Clinical Trials Sponsored by Ecogene 21

Total 1186 results

Laboratoire Boreaderme Inc.
Ecogene 21

Unknown

An Open Label Study to Evaluate the Safety and Efficacy of BOR15001L7 for the Treatment of Cold Sores in Patients With Recurrent Herpes Labialis

Recurrent Herpes Labialis
Daniel Gaudet
Ultragenyx Pharmaceutical Inc

Active, not recruiting

Safety and Effectiveness of Evinacumab for the Treatment of Homozygous Familial Hypercholesterolemia

Homozygous Familial Hypercholesterolemia

Canada
Nutrition 21, Inc.

Completed

Efficacy and Safety Study of Chromium Picolinate + Biotin on Glucose and Cholesterol Control in T2DM

Diabetes Mellitus, Type 2
Nutrition 21, Inc.

Completed

A 30 Day Acute Efficacy and Safety Study of Chromium Picolinate + Biotin on Glycemic Control in Overweight or Obese Subjects With T2DM

Diabetes Mellitus, Type 2

United States
Nutrition 21, Inc.

Unknown

Clinical Trial Evaluating the Viability of L. Casei + Fish Oil Capsules (Probiomega)

Signs and Symptoms, Digestive

United States
Texas A&M University
Nutrition 21, Inc.

Completed

Nutrition21 Study 1 (N21-1)

Nutritional Supplementation

United States
Pennington Biomedical Research Center
Nutrition 21, Inc.

Completed

Effects of Chromium Picolinate on Food Intake

Obesity | Atypical Depression

United States
Nutrition 21, Inc.
ALS Beauty and Personal Care

Recruiting

Effectiveness of a Novel Dietary Ingredient on Hair Growth and Skin's Appearance

Hair Thinning | Facial Skin Texture | Skin Ageing

United States
Danderyd Hospital
Karolinska Institutet; The 21 healthcare regions in Sweden

Not yet recruiting

Impact of Bariatric Surgery on Heart Disease Compared to Standard Care (MIMS)

Heart Diseases | Obesity, Morbid | Bariatric Surgery Candidate
Eccogene

Recruiting

ECC5004 RBA FE Study in Healthy Participants

Type 2 Diabetes Mellitus

United States
Eccogene

Recruiting

ECC5004 DDI Study With Atorvastatin, Rosuvastatin, Digoxin and Midazolam in Healthy Participants

Type 2 Diabetes Mellitus

United States
Eccogene

Recruiting

FTIH of ECC5004 in Healthy and Diabetic Participants

Type 2 Diabetes Mellitus

United States
Eccogene

Recruiting

FTIH of ECC4703 in Healthy Volunteers

Non-alcoholic Steatohepatitis (NASH)

United States
State University of New York - Upstate Medical...
Nutrition 21, Inc.

Terminated

Chromium Piccolinate in the Prevention of Weight Gain Induced by Serotonergic Medications Initiated on Psychiatric Inpatient Units.

Obesity | Weight Gain
Ove Andersen
Aalborg University; Albertslund Kommune; Gate 21; Chromaviso A/S

Completed

Circadian Adjusted LED Light's Effect in People Living in Elderly Housing (Lightel)

Elderly Housing Residents With Frailty or Dementia

Denmark
Celgene
Celgene Corporation

Completed

A Rollover Study for Patients Who Participated in Other Romidepsin Protocols

Lymphoma | Cancer

United States, United Kingdom
Celgene Corporation

Completed

3-part Study to Evaluate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of Multiple Doses of CC-220 and Relative Bioavailability of a Formulated CC-220 Capsule

Healthy Volunteers

United States
Celgene Corporation

Completed

A Pharmacokinetic And Pharmacodynamic Study Of Oral Lenalidomide (Revlimid) In Subjects With Low- Or Intermediate-1-Risk Myelodysplastic Syndromes

Low- or Intermediate-1-risk Myelodysplastic Syndrome (MDS)

United States
Celgene Corporation

Terminated

A Study to Assess the Efficacy and Safety of Lenalidomide in Combination With Cetuximab in Pre-treated Patients With KRAS Mutant Colorectal Cancer

Colorectal Cancer

Australia, Belgium, Germany, Italy, Spain, Sweden
Celgene Corporation

Completed

Efficacy and Safety Study of CC-5013 Monotherapy in Subjects With Myelodysplastic Syndromes

Myelodysplastic Syndromes

United States, Denmark, Australia, Belgium, Czech Republic, France, Germany, Greece, Italy, Netherlands, Russian Federation, Spain, Sweden, Switzerland, United Kingdom
Celgene Corporation

Completed

A Multicentre, Single-arm, Open-label Safety Study of Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma

Multiple Myeloma

Ireland, Spain, Australia, Austria, United Kingdom
Celgene Corporation

Completed

Study Comparing Amrubicin Versus Topotecan in Patients With Small Cell Lung Cancer Who Have Responded to Prior Therapy.

Small Cell Lung Cancer

United States
Celgene Corporation

Withdrawn

Study of Amrubicin With or Without Herceptin in Patients With Metastatic Breast Cancer

Metastatic Breast Cancer

United States
Celgene Corporation

Completed

D-MPH in the Treatment of Fatigue and Neurobehavioral Function Related to Chemotherapy in Adult Cancer Patients

Neoplasms | Fatigue

United States
Celgene Corporation

Completed

A Study to Access the Safety/Efficacy of Thalidomide in the Treatment of Anemia in Patients With Myelodysplastic Syndromes

Myelodysplastic Syndromes

United States
Celgene
Celgene Corporation

Completed

Study of Orally Administered Enasidenib (AG-221) in Adults With Advanced Solid Tumors, Including Glioma, or Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation

Glioma | Solid Tumor | Angioimmunoblastic T-cell Lymphoma | Chondrosarcoma | Intrahepatic Cholangiocarcinoma

United States, France
Celgene
Celgene Corporation

Terminated

A Phase 1 Trial of ABI-011 in Patients With Advanced Solid Tumors or Lymphomas

Advanced Solid Tumors

United States
Celgene
Celgene Corporation

Completed

Combination Study of Pomalidomide, Marizomib, and Low-Dose Dexamethasone in Relapsed and Refractory Multiple Myeloma

Multiple Myeloma | Refractory Multiple Myeloma | Multiple Myeloma in Relapse

United States, Australia
Celgene Corporation

Completed

A Study of Combination Thalidomide Plus Dexamethasone Therapy vs. Dexamethasone Therapy Alone in Previously Untreated Subjects With Multiple Myeloma

Multiple Myeloma

United States, Spain, Australia, Canada, United Kingdom, Italy, Switzerland, Bulgaria, Poland, Ukraine, Belgium, Germany, Hungary, Ireland, Israel, Russian Federation
Celgene Corporation

Terminated

Prevention of Restenosis Following Revascularization

Vascular Disease, Peripheral

United States
Celgene Corporation

Completed

A Multicenter, Single-Arm, Open-Label Expanded Access Program for Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma

Relapsed or Refractory Multiple Myeloma

Germany
Celgene Corporation

Terminated

A Study to Evaluate Lenalidomide Combined With Dexamethasone in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Diffuse Large B-cell Lymphoma

United States, Canada, Australia
Celgene Corporation

Completed

A Study of CC-5013 in the Treatment of Complex Regional Pain Syndrome (CRPS) (CRPS)

Complex Regional Pain Syndrome (RSD)

United States
Celgene Corporation

Completed

Phase I Trial of CC-8490 for the Treatment of Subjects With Recurrent/Refractory High-Grade Gliomas

Glioblastoma | Malignant Gliomas

United States
Celgene
Celgene Corporation

Completed

A Single Agent Phase II Study of Romidepsin (Depsipeptide, FK228) in the Treatment of Cutaneous T-cell Lymphoma (CTCL)

Cutaneous T-cell Lymphoma

United States, France, Germany, Poland, Russian Federation, United Kingdom
Celgene Corporation

Completed

Effect of UV Exposure on the PD of Multiple Doses of CC-90001 and Pilot Food Effect Study

Healthy Subjects

United States
Celgene Corporation

Terminated

Phase 1 Study of CC-486 in Japanese Subjects With Hematological Neoplasms

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Multiple Myeloma | Hodgkin Lymphoma | Chronic Myelomonocytic Leukemia | Non-Hodgkin Lymphoma

Japan
Celgene Corporation

Completed

First-in-human Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of CC-90001

Healthy Volunteers

United States
Celgene Corporation

Withdrawn

Study to Determine Efficacy and Safety of CC-486 With Nab-Paclitaxel Versus Nab-Paclitaxel in Patients With Chemotherapy naïve Metastatic Melanoma

Metastatic Melanoma
Celgene Corporation

Terminated

Study to Evaluate the Efficacy and Safety of Lenalidomide in the Treatment of Complex Regional Pain Syndrome Type 1 (CRPS-002)

Complex Regional Pain Syndrome, Type I

United States
Celgene Corporation

Unknown

A Single-arm Safety Study of Transplantation Using Umbilical Cord Blood and Human Placental-derived Stem Cells From Partially Matched Related Donors in Persons With Certain Malignant Blood Diseases and Non-malignant Disorders (HPDSC)

Hematologic Malignancies

United States
Celgene Corporation

Completed

Use of Nanoparticle Paclitaxel (ABI-007) for the Prevention of In-Stent Restenosis (SNAPIST-III)

Coronary Restenosis
Celgene Corporation

Completed

Study to Evaluate the Efficacy and Safety of Lenalidomide in the Treatment of Painful Lumbar Radiculopathy

Radiculopathy

United States
Celgene Corporation

Completed

A Phase II Study of Continuous Versus Syncopated Dosing of CC-5013 for the Treatment of Refractory Multiple Myeloma

Multiple Myeloma

United States
Celgene Corporation

Terminated

Study to Determine the Optimal Biologic Dose of CC-401 in Subjects With High-Risk Myeloid Leukemia

Myeloid Leukemia

United States
Celgene Corporation

Completed

Safety and Efficacy of CC-4047 in Subjects With Metastatic Hormone Refractory Prostate Cancer (HRPC)

Prostate Cancer

United States
Celgene Corporation

Completed

Study to Compare the Efficacy and Safety of Two CC-5013 Dose Regimens in Subjects With Metastatic Malignant Melanoma

Melanoma | Neoplasm Metastasis

United States, Canada
Sussex NHS Research Consortium
University of Surrey; NHS Research and Development; Lab 21, Cambridge

Completed

Impact of a Gene Test for Susceptibility to Lung Cancer in Smokers

Smoking Cessation

United Kingdom
Celgene

Not yet recruiting

A Study to Evaluate the Effect of Cytochrome P450 (CYP) 3A Inhibitor (Itraconazole) and Inducer (Rifampin) on the Drug Levels of Golcadomide (BMS-986369) in Healthy Participants

Healthy Volunteers

United States
Celgene

Not yet recruiting

Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma (GOLSEEK-1)

Large B-cell Lymphoma

United States, Canada, Argentina, Australia, Austria, Brazil, Bulgaria, Chile, China, Colombia, Croatia, Czechia, Denmark, Finland, France, Germany, Greece, Hungary, Japan, Korea, Republic of, Malaysia, Mexico, New Zealand, Norway, Poland, Portug... and more

3

Subscribe